# Dupilumab

## Dupixent inj 300mg/2mL

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | IDUPI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Indications        | Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | Atopic dermatitis， Moderate to severe Adult， initial， 600 mg (two 300 mg injections) subQ， then 300 mg subQ every other week Adolescents 12 to 17 Years Old， if <60kg 400 mg (two 200 mg injections) subQ， then 200 mg subQ every other week. If>60kg 600 mg (two 300 mg injections) subQ， then 300 mg subQ every other week. Concomitant therapy: Use with or without topical steroids; reserve concomitant use with topical calcineurin inhibitors for problem areas only (eg， face， neck， intertriginous and genital areas Asthma (Moderate to Severe)， Adjunct; oral corticosteroid-dependent (12 years or older) Loading， 400 mg (two 200 mg injections) subQ followed by 200 mg every other week or an initial loading dose of 600 mg (two 300 mg injections) subQ followed by 300 mg every other week. For patients with oral corticosteroid-dependent asthma or with comorBID moderate-to-severe atopic dermatitis， start with the 600-mg dose followed by 300 mg every other week |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Contraindications  | Known hypersensitivity to dupilumab or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | >10%: Local: Injection site reaction (10% to 18%) 1% to 10%: Gastrointestinal: Oral herpes simplex infection (4%) Hematologic & oncologic: Eosinophilia (<2%) Immunologic: Antibody development (6% to 9%; neutralizing: 2% to 4%) Infection: Herpes simplex infection (2%) Ophthalmic: Conjunctivitis (10%)， eye pruritus (1%) Respiratory: Oropharyngeal pain (2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Pregnancy          | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

